Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03696069 · ClinicalTrials.gov registry record
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 501
- Enrollment target
NCT03696069: Completed study, sponsored by Bristol-Myers Squibb.
NCT03696069 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 501 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03696069 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 501 participants
- Enrollment target
Study Summary
The goal of the study is to understand the treatment patterns for immunotherapy agents and BRAF/MEK inhibitors used in the treatment of advanced melanoma
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2019-01-09 |
| Est. Completion | 2020-02-14 |
What the finished NCT03696069 record still lists
NCT03696069 is an observational study that tracks outcomes without assigning an intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03696069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03696069 about?
NCT03696069 is a clinical study titled "A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma". The goal of the study is to understand the treatment patterns for immunotherapy agents and BRAF/MEK inhibitors used in the treatment of advanced melanoma
What is the current status of trial NCT03696069?
This trial is currently completed. The enrollment target is 501 participants. The study started on 2019-01-09. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT03696069?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03696069?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI